Epicene team, University of Bordeaux, Inserm, Bordeaux Population Health Research Centre, Epicene Team, UMR 1219, 33000, Bordeaux, France; Department of Palliative Medicine, CHU Bordeaux, 33000, Bordeaux, France.
Epicene team, University of Bordeaux, Inserm, Bordeaux Population Health Research Centre, Epicene Team, UMR 1219, 33000, Bordeaux, France.
Public Health. 2021 Jun;195:24-31. doi: 10.1016/j.puhe.2021.03.020. Epub 2021 May 24.
More than half of cancer patients require palliative care; however, inequality in access and late referral in the illness trajectory are major issues. This study assessed the cumulative incidence of first hospital-based palliative care (HPC) referral, as well as the influence of patient-, tumor-, and care-related factors.
This is a retrospective population-based study.
The study included patients from the 2014 population-based cancer registry of Gironde, France. International Classification of Diseases, Tenth Revision, coding for palliative care identified HPC referrals from 2014 to 2018. The study included 8424 patients. Analyses considered the competing risk of death and were stratified by initial cancer prognosis (favorable vs unfavorable [if metastatic or progressive cancer]).
The 4-year incidence of HPC was 16.7% (95% confidence interval, 16.6-16.8). Lung cancer led to more referrals, whereas breast, colorectal, and prostatic locations were associated to less frequent HPC compared with other solid tumors. Favorable prognosis central nervous system tumors and unfavorable prognosis hematological malignancies also showed less HPC. The incidence of HPC was higher in tertiary centers, particularly for older patients. In the favorable prognosis subgroup, older and non-deprived patients received more HPC. In the unfavorable prognosis subgroup, the incidence of HPC was lower in patients who lived in rural areas than those who lived in urban areas.
One-sixth of cancer patients require HPC. Some factors influencing referral depend on the initial cancer prognosis. Our findings support actions to improve accessibility, especially for deprived patients, people living in rural areas, those with hematological malignancies, and those treated outside tertiary centers. In addition, consideration of age as factor of HPC may allow for improved design of the referral system.
超过一半的癌症患者需要姑息治疗;然而,在疾病进程中,获得姑息治疗的机会不平等和转诊较晚是主要问题。本研究评估了首次基于医院的姑息治疗(HPC)转诊的累积发生率,以及患者、肿瘤和护理相关因素的影响。
这是一项回顾性基于人群的研究。
本研究纳入了来自法国吉伦特 2014 年基于人群的癌症登记处的患者。国际疾病分类,第十版,姑息治疗编码确定了 2014 年至 2018 年的 HPC 转诊。本研究纳入了 8424 名患者。分析考虑了死亡的竞争风险,并按初始癌症预后(有利与不利[如果是转移性或进展性癌症])进行分层。
HPC 的 4 年发生率为 16.7%(95%置信区间,16.6-16.8)。肺癌导致更多的转诊,而乳腺癌、结直肠癌和前列腺癌与其他实体瘤相比,HPC 较少。有利预后的中枢神经系统肿瘤和不利预后的血液恶性肿瘤也显示出较少的 HPC。三级中心的 HPC 发生率较高,尤其是对老年患者。在有利预后亚组中,年龄较大和非贫困患者接受更多的 HPC。在不利预后亚组中,居住在农村地区的患者 HPC 发生率低于居住在城市地区的患者。
六分之一的癌症患者需要 HPC。影响转诊的一些因素取决于初始癌症的预后。我们的研究结果支持采取行动提高可及性,特别是为贫困患者、生活在农村地区的患者、血液恶性肿瘤患者和在三级中心以外接受治疗的患者。此外,考虑年龄作为 HPC 的因素可能有助于改善转诊系统的设计。